Showing 1 - 3 results of 3 for search 'Kengo Nagashima', query time: 0.01s Refine Results
  1. 1
    Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)

    Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Author Correction: Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding cells: a pilot study

    Author Correction: Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding cells: a pilot study by Akihito Hishikawa, Erina Sugita Nishimura, Norifumi Yoshimoto, Ran Nakamichi, Eriko Yoshida Hama, Wataru Ito, Tomomi Maruki, Kengo Nagashima, Ryoko Shimizu‑Hirota, Hiromasa Takaishi, Hiroshi Itoh, Kaori Hayashi

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding cells: a pilot study

    Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding cells: a pilot study by Akihito Hishikawa, Erina Sugita Nishimura, Norifumi Yoshimoto, Ran Nakamichi, Eriko Yoshida Hama, Wataru Ito, Tomomi Maruki, Kengo Nagashima, Ryoko Shimizu-Hirota, Hiromasa Takaishi, Hiroshi Itoh, Kaori Hayashi

    Published 2024-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: